ARISTOTLE trial (apixaban vs warfarin)

ARISTOTLE  2011 (Bristol-Myer-Squibb)

Population - 18,201 patients with atrial fibrillation with at least one risk factor

Intervention - apixaban 5 mg/tab BID vs warfarin (target INR 2-3), ff up 1.8 years

Outcome - Apixaban was associated with 21% risk reduction in stroke or systemic embolism, 31 % reduction in bleeding, 11% reduction in all-cause mortality

Method: randomized controlled trial  (RCT)

Posted by Dr. Ted Alviar at 2/10/2012 5:08 AM
Categories: Clinical trials:Cardiology
Tags: Clinical trials
 
Trackbacks
Trackback specific URL for this post
  • No trackbacks exist for this post.
Comments
  • No comments exist for this post.
Leave a comment

Submitted comments are subject to moderation before being displayed.

 Name (required)

 Email (will not be published) (required)

Your comment is 0 characters limited to 3000 characters.